Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2011-05-17
2011-05-17
Bunner, Bridget E (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C530S391700, C530S402000, C424S085200, C435S320100, C435S471000, C435S069520, C435S810000, C536S023500
Reexamination Certificate
active
07943738
ABSTRACT:
The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
REFERENCES:
patent: 6482923 (2002-11-01), Shi et al.
patent: 6548633 (2003-04-01), Edwards et al.
patent: 6569645 (2003-05-01), Chen et al.
patent: 6635443 (2003-10-01), Shi et al.
patent: 2002/0102639 (2002-08-01), Shaughnessy
patent: WO 99/14240 (1999-03-01), None
patent: WO 99/35263 (1999-07-01), None
patent: WO 99/61617 (1999-12-01), None
patent: WO 00/15759 (2000-03-01), None
patent: WO 00/20593 (2000-04-01), None
patent: WO 00/37491 (2000-06-01), None
patent: WO 00/55204 (2000-09-01), None
patent: WO 00/60080 (2000-10-01), None
patent: WO 01/00806 (2001-01-01), None
patent: WO 01/16318 (2001-03-01), None
patent: WO 01/49728 (2001-07-01), None
patent: WO 01/57202 (2001-08-01), None
patent: WO 01/59120 (2001-08-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 01/90358 (2001-11-01), None
Shi et al, The Journal of Biological Chemistry, 2000, vol. 275, pp. 19167-19176.
Daniel et al., “Mapping of linear antigenic sites on the S glycoprotein of a neurotropic murine coronavirus with synthetic peptides: A combination of nine prediction algorithms fails to identify relevant epitopes and peptide immunogenicity is drastically influenced by the nature of the protein carrier,”Virology, 202:540-549, 1994.
Hudson et al.,Practical Immunology, 2ndEdition, Blackwell Scientific Publications, 1980.
Lederman et al., “A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4,”Mol. Immunol, 28:1171-1181, 1991.
Li et al., β-endorphin omission analogs: Dissociation of immunoreactivity from other biological activities,Proc. Natl. Acad. Sci. USA, 77:3211-3214, 1980.
Matsudaira et al., “Sequence from picomole quantities of proteins electroblotted onto polyvinyl difluoride membranes”,J. Biol. Chem., 262:10035-10038, 1987.
Tian et al., Evi27 encodes a novel membrane protein with homology to the IL-17 receptor,Oncogene, 19:2098-2109, 2000.
Van Regenmortel, M. H. V., “From absolute to exquisite specificity. Reflection son the fuzzy nature of species, specificity and antigenic sites,”J. Immunol. Methods, 216:37-48, 1998.
Wells, James A., “Addivity of mutational effects in proteins”,Biochem., 29(37):8509-8517, 1990.
Yao et al., “Molecular characterization of the human interleukin (IL)-17 receptor,”Cytokine, 9:794-800, 1997.
International Search Report for PCT/US01/08688, European Patent Office, mailed Feb. 14, 2002.
Elliott Gary S.
Jing Shuqian
Medlock Eugene
Nquyen Hung Q.
Sibiger Scott Michael
Amgen Inc.
Bunner Bridget E
Hamud Fozia M
Klaniecki James E.
LandOfFree
IL-17 receptor like molecules and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-17 receptor like molecules and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-17 receptor like molecules and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692618